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Abstract
Background—Several observational studies have reported that metformin may be associated 
with reduced risk of breast cancer; however, many of these studies were affected by time-related 
biases such as immortal time bias and time-window bias. This study aimed to examine the relative 
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risk of breast cancer for older women initiating metformin versus sulfonylureas while avoiding 
such biases.
Methods—The study cohort consisted of women aged 65+ who initiated monotherapy with 
metformin (n=45,900) or sulfonylureas (n=13,904) and were free of cancer and renal disease 
within 6 months before treatment initiation using 2007–2012 US Medicare claims data. We 
followed treatment initiators for incident breast cancer, and estimated hazard ratios using weighted 
Cox models. Unmeasured confounding by body mass index and smoking was further adjusted by 
propensity score calibration using external information from Medicare Current Beneficiary Survey 
2006–2009 panels.
Results—During 58,835 and 16,366 person-years of follow-up, 385 initiators of metformin 
treatment and 95 of sulfonylurea were diagnosed with breast cancer. Metformin initiators did not 
have a reduced risk of breast cancer compared with sulfonylurea initiators (hazard ratio: 1.2; 95% 
confidence interval: 0.94, 1.6). Externally controlling for body mass index and smoking did not 
affect the estimates.
Conclusion—The findings of this study provide no support for a reduced risk of breast cancer 
after initiation of metformin compared with a clinical alternative in older women. This study is 
limited by the relatively short follow-up time and we cannot exclude the possible benefits of long-
time metformin use on breast cancer risk.
Keywords
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Breast cancer is the most common cancer and is the second leading cause of cancer death for 
women in the United States. The cost of breast cancer care in 2010 was estimated at 16.5 
billion dollars in US, the highest among all cancer sites.2 Diabetes is associated with a 
20%-40% increased risk of breast cancer in women.3 As the first-line treatment for type 2 
diabetes 4, metformin has received much attention due to its potential to reduce cancer 
incidence and improve outcomes, in particular, for breast cancer.5–7
Evidence from preclinical and clinical studies suggests that metformin has anti-tumor 
properties and may reduce incidence and mortality of breast cancer.9,10 A meta-analysis of 
seven observational studies found a 17% decreased risk of breast cancer associated with 
metformin, and reported that metformin use for 3 years or longer was associated with 25% 
reduced risk of breast cancer.11 Despite several observational studies suggesting 
chemopreventive effects of metformin on breast cancer, concerns have been raised that many 
of these studies were subject to time-related biases (e.g., immortal time bias and time-
window bias) which would lead to an apparent protective effect in the absence of a real 
effect or magnify any potential beneficial effect of metformin on cancer incidence.12
Apart from time-related bias, unmeasured confounding is another major potential source of 
bias in observational studies, especially those based on claims data. Claims data are not 
collected for research purposes and usually lack information on some risk factors for breast 
cancer in postmenopausal women, such as body mass index (BMI) and smoking.13–15 
Unmeasured confounding by BMI and smoking is a major concern in studies comparing 
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metformin users with non-users. In studies comparing metformin initiators with initiators of 
a clinical alternative for patients with type 2 diabetes, the potential for unmeasured 
confounding by BMI and smoking is largely reduced.
Observational studies are useful to evaluate drug safety and effectiveness in real world 
settings.16,17 If incorrectly designed, however, they can suffer from various types of biases 
leading to spurious results. For example, observational findings on benefits of statins in 
patients with chronic obstructive pulmonary disease were recently disproved by a 
randomized trial.18 The discordance between observational studies and randomized trials is 
often portrayed as being the results of a fatal flaw inherent to observational studies, but such 
a view ignores the fact that not all observational studies are created equal. Observational 
studies need to be designed using rigorous methods to reduce the potential for bias.12,19,20 
Our objective was to investigate whether metformin reduces the risk of breast cancer in a 
large, nationally representative older population in the US, by conducting a state-of-the-art 
new user cohort study with a clinical alternative.20
METHODS
Study population
Our study cohort was selected from women aged 65 years or older enrolled in Medicare 
between 2007 and 2012. Medicare is the United States federal health insurance plan, 
administered by the Centers for Medicare and Medicaid Services. Medicare provides 
medical coverage for citizens aged 65 years or older, with certain disabilities, or with End-
Stage Renal Disease (ESRD). The Medicare database is composed of Part A (inpatient), Part 
B (outpatient physician services), and Part D (dispensed prescription drugs) claims and also 
contains patients’ demographics. Our study cohort included only new users of metformin 
and sulfonylureas. To be eligible as a new user, women were required to be aged 65 years or 
older, to have had at least 6-month continuous enrollment in Medicare Parts A, B, and D 
before initiation, and to have initiated monotherapy with metformin or sulfonylureas after at 
least 6 months without a prescription for any anti-hyperglycemic drugs. Given that 
metformin and sulfonylureas were primarily indicated for diabetes in the elderly, we 
assumed that patients receiving metformin or sulfonylureas were diagnosed with diabetes, 
thus not restricting the study cohort to those with a prior diagnosis code for diabetes. 
Initiation was defined as not having received any anti-diabetic treatment within 6 months 
prior to the first prescription of metformin or sulfonylureas and having had at least 1 refill 
within 90 days after the end of days-supply of the first prescription. The date of the first 
refill was defined as the index date. Patients were excluded if they had a prior diagnosis of 
renal disease or cancer during the 6 months before the index date. Patients with renal disease 
were excluded because metformin is contraindicated in these patients.4 The flowchart of 
study population is shown in eFigure 1.
Follow-up for breast cancer
The outcome of interest was a diagnosis of incident breast cancer during follow-up, 
including both in situ and invasive breast cancer, identified by having at least two ICD-9 
diagnosis codes for breast cancer on different dates within 60 days. The date of the first 
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diagnosis was used to define the outcome date. This algorithm has been previously validated 
in a Medicare population.21
We used both as-treated (primary) and intention-to-treat (secondary) analyses. Because 
breast cancer has a long preclinical phase, we assumed a 180-day induction period for 
cancer pathogenesis and a 180-day carry-over effect or latency period for cancer detection in 
the analysis. The as-treated approach defined follow-up based on actual exposure to the 
initial treatment. Patients were considered to be exposed to the initial treatment (i.e., 
metformin or sulfonylureas) until treatment changes. Treatment changes included drug 
discontinuation, switch to or a subsequent addition of other anti-diabetic drug classes to the 
index prescription. Treatment discontinuation was defined as no further refill within the days 
supply plus a 90-day grace period. To account for induction and latency periods, follow-up 
started on 180 days after the index date, and ended with the earliest of the following events: 
180 days after treatment changes, any cancer diagnosis except for non-melanoma skin 
cancer, death, enrollment gap in Medicare Part A, B, and D enrollment greater than 1 month, 
or end of study (31 December 2012). In the intention-to-treat analysis (first treatment carried 
forward), patients were considered to be exposed to the initial treatment until administrative 
censoring, ignoring any subsequent treatment changes. It followed patients from 180 days 
after the index date and until the date of any cancer diagnosis except for non-melanoma skin 
cancer, death, enrollment gap in Medicare Part A and B enrollment greater than 1 month, or 
end of study, irrespective of any treatment change or discontinuation.
Confounding control
We used propensity scores to control for measured confounding.22 For each patient, the 
probability of receiving metformin vs sulfonylureas was estimated using a logistic regression 
model (i.e., the propensity score model). The propensity score model included demographic 
and clinical variables that we identified as potential confounders or risk factors for breast 
cancer, as well as frequencies of healthcare utilization. All covariates were defined based on 
available information during the 6-month period prior to initiation. We standardized the 
distribution of these covariates to that of the metformin initiators using weights of 1 for 
metformin initiators and the odds of propensity score for sulfonylurea initiators.23
Statistical analysis
We summarized baseline characteristics by study cohort and further adjusted them by 
propensity score weighting. For each treatment group, we estimated the crude and weighted 
incidence rates for breast cancer using a Poisson regression model. We then used a Cox 
proportional regression model to estimate the crude and weighted hazard ratios (HRs) of 
breast cancer with 95% confidence intervals (CIs) using a robust variance estimation for the 
weighted model. To explore potential trends of the HRs over time, we estimated the HRs in 
sequential 6-month intervals following the index date. We also performed subgroup 
analyses, stratified by age group, race, and baseline use of statins.
Several sensitivity analyses were pre-planned. First, given the unresolved concerns as to 
whether sulfonylureas have an effect on breast cancer risk, we compared the risk of breast 
cancer in new users of metformin vs two alternative active comparator groups: (1) new users 
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of thiazolidinediones or dipeptidyl peptidase-4 inhibitors, both of which are also oral 
hypoglycemic agents; (2) diabetic patients who initiated angiotensin-converting-enzyme 
inhibitors without prior use of any anti-diabetic drugs. Second, to minimize the potential 
misclassification in defining treatment use during follow-up and diabetic patients, we 
repeated the primary analyses with a longer grace period of 180 or 365 days and restricting 
to new users who had a diagnosis code for diabetes within 6 months before initiation, 
respectively. Because detection of early renal disease might be differential between 
treatment cohorts, we conducted an analysis including prior renal disease and an analysis 
excluding those patients with severe renal disease (i.e., chronic kidney disease stage 4 and 
5). Additionally, we restricted the outcome of interest to invasive breast cancer only. Finally, 
to evaluate the robustness of the assumptions of induction and latency periods, we repeated 
the main analysis while varying the induction period from 0 to 365 days (for both the as-
treated and intention-to-treat analysis) and the latency period from 0 to 730 days (for the as-
treated analysis).
External Validation Study
To quantify the extent of residual confounding by BMI and smoking that are unavailable in 
Medicare claims, we conducted a cross-sectional study using external data from the 
Medicare Current Beneficiary Survey (MCBS) 2006–2009 panels to identify women 
initiating metformin or sulfonylureas. The MCBS is a survey conducted within a sample of 
the Medicare population. The MCBS participants were sampled to be generally 
representative of the Medicare population but with an oversampling of the disabled and the 
oldest-old (85 years of age or over). New use was defined as initiation of monotherapy with 
metformin or sulfonylureas after at least 6 months without a prescription for metformin or 
sulfonylureas. Given the sample size of the MCBS is relatively modest and therefore that the 
absolute number of women initiating these drugs is small in the MCBS, initiation was 
defined by requiring only one prescription. We extracted data on height, weight, and self-
reported smoking status from the MCBS Cost & Use module in the same year of initiation. 
BMI was calculated by weight (kilogram) divided by height (meter) squared, and was 
treated as a continuous variable as well as a categorical variable (<25 as normal; ≥25 and 
<30 as overweight; and ≥30 as obese). Individual smoking status was grouped into never and 
ever smoker. History of comorbidity and co-medication at baseline were retrieved from the 
linked Medicare claims data. We quantified the association of BMI and smoking with the 
initiation of metformin vs sulfonylureas independent of other covariates, fitting a propensity 
score model equivalent to the one in the Medicare study as far as possible, because the small 
number of initiators in the MCBS limited the number of covariates that could be included in 
logistic regression models.
We implemented propensity score calibration to correct the effect estimates in the Medicare 
study for confounding by BMI and smoking.25,26 Briefly, two propensity scores were 
estimated within the MCBS data: the error-prone propensity score based on covariates 
available in claims, and the gold-standard propensity score based on BMI and smoking 
status in addition to the variables available in claims. Based on these two propensity scores 
in the MCBS study and the estimates from the Cox model in the Medicare study, we applied 
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regression calibration to correct regression coefficients in the Medicare cohort using the SAS 
macro “%blinplus.”27
All statistical analyses were performed with the SAS 9.3 (SAS Institute, Cary NC). This 
study was approved from the Institutional Review Board (IRB) expedited review at the 
University of North Carolina at Chapel Hill.
RESULTS
We identified 45,900 and 13,904 women who initiated metformin or sulfonylureas who met 
our inclusion criteria, respectively. Compared with metformin initiators, sulfonylurea 
initiators were older, had more cardiovascular disease (i.e., congestive heart failure and 
ischemic heart disease), and were more likely to have been admitted to a hospital and visited 
an emergency room in the 6 months prior to the index date (Table 1). Metformin initiators 
were more likely to have received a prescription for statins, a mammogram, or a lipid test 
compared with sulfonylurea initiators. After propensity score weighting, the marginal 
distributions of measured characteristics were comparable between women initiating 
metformin and sulfonylureas.
In our primary, as-treated analysis, 385 metformin initiators and 95 sulfonylurea initiators 
were diagnosed with breast cancer over 58,835 and 16,366 person-years of follow-up, 
respectively (Table 2). The crude incidence rates of breast cancer per 1,000person-years 
were 6.5 (95% CI: 5.9, 7.2) and 5.8 (95% CI: 4.7, 7.1) in metformin and sulfonylureas 
initiators, respectively. After propensity score weighting the sulfonylurea initiators to 
minimize any measured baseline differences between the treatment groups, the incidence 
rate was 5.5 (95% CI: 4.9, 6.2) in sulfonylureas initiators. The weighted HR comparing 
metformin with sulfonylureas initiators was 1.2 (95% CI: 0.94, 1.6) (Table 2). The effect 
estimate from the intention-to-treat analysis was unchanged (adjusted HR: 1.2; 95% CI: 
0.96, 1.4).
In Figure 1A, we examined the risk of breast cancer associated with metformin stratified by 
duration of treatment after initiation. No decreasing trend was observed after initiation and 
HR estimates were all close to the null. Figure 1B shows the breast cancer risk for 
metformin vs sulfonylureas initiators across several subgroups. There was no indication of a 
protective association across the age groups and in either subgroup defined by prior statin 
use. However, we observed a possibly reduced risk for breast cancer associated with 
metformin in black women (HR: 0.79; 95% CI: 0.39, 1.6, for the as-treated analysis) but the 
confidence interval was wide due to the small number of events (n=36 for the as-treated 
analysis). The results were similar in the as-treated and intention-to-treat analyses (eFigure 
4). We also conducted several sensitivity analyses. No association with breast cancer was 
observed when comparing metformin initiators to initiators of thiazolidinediones or 
dipeptidyl peptidase-4 inhibitors or to diabetic initiators of angiotensin-converting-enzyme 
inhibitors (eTable 1). Similarly, metformin was not associated with a lower risk of breast 
cancer while varying the length of the induction period, the latency period, or the grace 
period (eTable 2–4).
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We further controlled for unmeasured confounding by BMI and smoking with propensity 
score calibration. A total of 118 and 79 female initiators of metformin and sulfonylureas 
were identified from the MCBS. Being obese (BMI: ≥30) and ever smoking were associated 
with metformin initiation (Table 3). These associations were diminished after multivariable 
adjustment (mainly driven by age effects), indicating little difference in associations with 
BMI and smoking status conditional on controlling for other differences. Thus, the hazard 
ratio for breast cancer comparing metformin vs sulfonylureas remained unchanged after the 
propensity score calibration correction (eTable 5).
DISCUSSION
In this large, population-based study using an active comparator, new-user cohort design we 
found that older women initiating metformin did not have a lower risk for breast cancer than 
women initiating a therapeutic alternative. The findings were consistent across all sensitivity 
analyses. Despite our observation of a possible tendency towards a lower risk of breast 
cancer associated with metformin in African American women, our result showing no 
beneficial association was consistent across several subgroup and sensitivity analyses.
Several studies have reported a lower risk of breast cancer associated with metformin, but 
may have suffered from time-related biases.28–30 The greatest benefits of metformin on 
reducing breast cancer risk were observed in a case-control study conducted within the 
Clinical Practice Research Datalink (CPRD).28 Long-term use of metformin (≥ 40 
prescriptions) was associated with a marked reduction in breast cancer risk compared with 
no use of metformin (Odds Ratio (OR): 0.44; 95% CI: 0.24, 0.82). A case-control study 
from Denmark reported a reduced risk of breast cancer comparing ≥ 1-year use of 
metformin to both no use of metformin (OR: 0.81; 95% CI: 0.63, 0.96) and use of other anti-
diabetic drugs (OR: 0.78; 95% CI: 0.59, 1.0).29 A beneficial association with metformin was 
also observed in women with 5 years of metformin use (OR: 0.83; 95% CI: 0.56, 1.2) and 
among women with diabetes complications (OR: 0.67; 95% CI: 0.45, 1.0).29 Metformin may 
have benefits on breast cancer risk after long-term use, but at least part of these inverse 
associations may also be due to time-window bias.12 This type of bias arises from unequal 
time windows of exposure opportunity between cases and controls because cases and 
controls were not matched on time since onset of diabetes or since the first antidiabetic 
prescription in this study.
Our null results are consistent with most of prior studies not affected by time-related biases. 
Three cohort studies, all using the UK Clinical Practice Research Datalink (CPRD), found 
no association of metformin versus sulfonylureas with the risk of breast cancer (HR: 1.0; 
95% CI: 0.79, 1.4331; HR: 0.96; 95% CI: 0.76, 1.232; HR: 1.0; 95% CI 0.82, 1.333). Re-
analyses of two randomized clinical trials showed no beneficial effect of metformin versus 
rosiglitazone on breast cancer risk but were limited by small numbers of breast cancer cases 
(n<20).34 In contrast, in a cohort study from the Netherlands, the risk of breast cancer was 
slightly lower among metformin initiators compared with sulfonylureas initiators (HR: 0.95; 
95% CI: 0.91, 0.98).35 However, this study included women age 18 or older, representing a 
much younger study population than our Medicare-based cohort. Metformin might act 
differently on breast cancer in pre- and postmenopausal women. The Women’s Health 
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Initiative study found a reduced risk of invasive breast cancer associated with metformin in 
post-menopausal women (HR: 0.75; 95% CI: 0.57, 0.99).36 Drug exposures in the Women’s 
Health Initiative study were self-reported and collected through questionnaires with unequal 
intervals, likely impeding the accurate identification of the date of treatment initiation.19 Our 
study used data on pharmacy-dispensed prescriptions that provide longitudinal drug data, 
which enables the clear identification of initiators of drugs and to address issues related to 
the time since drug initiation.37
Our findings suggest that metformin may be associated with a lower risk of breast cancer 
among African American women, although this estimate was imprecisely measured. African 
Americans are more likely to develop triple receptor-negative breast cancer than white 
women.38,39 One cohort study of 130 patients with triple receptor-negative breast cancer 
found that use of metformin was associated a lower risk of distant metastases (HR: 0.61; 
95% CI: 0.33, 1.15)40, supported by preclinical studies.41,42 One plausible explanation for 
these findings is that metformin may have a favorable effect on triple receptor-negative 
breast cancer which is more prevalent in African Americans. In the Women’s Health 
Initiative study, metformin use was associated with a greater reduction in the risk of human 
epidermal receptor 2 (HER2)-negative breast cancer (HR: 0.58; 95% CI: 0.40, 0.84), 
compared with overall invasive breast cancer (HR: 0.75; 95% CI: 0.57, 0.99), despite the 
fact that the two CIs overlapped.36 Our subgroup analysis is limited by the small number of 
breast cancers in African American women observed, thus chance is a plausible alternative 
explanation.
We used external information from the MCBS to quantify the unmeasured confounding by 
BMI and smoking on the association between metformin and breast cancer incidence. 
Obesity and smoking were associated with higher odds of receiving metformin vs 
sulfonylureas. However, these associations became weak after adjusting for other variables 
in the propensity score model, indicating minimal independent effect of BMI and smoking 
of metformin prescribing relative to sulfonylureas and little residual confounding by BMI 
and smoking on the association between metformin and breast cancer incidence. This lack of 
effect on relative prescribing given the indication to initiate treatment with oral anti-diabetic 
drugs is a direct result of the state-of-the art new user, active comparator cohort design.43 We 
consistently observed no metformin–breast cancer associations after implementing 
propensity score calibration. We acknowledge the possibility that similar results before and 
after applying propensity score calibration may be due to inadequate control using 
propensity score calibration. However, we observed little difference in BMI and smoking 
after controlling for other measured variables, indicating low potential for unmeasured 
confounding due to BMI and smoking.
Our study has several limitations. First, it is limited by the short follow-up time (maximum 
of 4.5 years). Diabetes treatment regimens are usually modified over time for adequate 
glycemic control as diabetes progresses, so the observed duration on the initial treatment is 
limited by actual treatment dynamics (median: 0.86 year; interquartile range: 0.38, 1.8) in 
the as-treated analysis. In the intention-to-treat analysis that ignored treatment changes 
during follow-up, the follow-up time was double (median: 1.8 years; interquartile range: 
0.82, 3.1), but still short for evaluating a cancer outcome. Thus, we cannot exclude the 
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possibility of a beneficial effect of long-term use of metformin on breast cancer risk. 
Secondly, we have used a new user design with an active comparator to reduce confounding 
by indication. However, sulfonylureas are not recommended as the first-line treatment and 
the washout period to define new use is relatively short. Thus, our study population may 
include some patients with prior treatment and sulfonylurea initiators may have more severe 
diabetes on average than metformin initiators. This could lead to a lower baseline risk of 
breast cancer in metformin initiators resulting in a reduced HR but cannot explain our 
finding. Thirdly, we only started follow-up after the second dispensed prescription (i.e., the 
index date) because patients with a second prescription are more likely to be actually 
exposed to the drug. This may have introduced some selection bias but increases the 
likelihood that the patients actually took the drugs of interest. We also calculated percentage 
of days covered within the first year after initiation as a proxy of adherence among patients 
who continued treatment for ≥12 months and found no difference in adherence (eTable 7).
Our results may be confounded by unmeasured risk factors for breast cancer if these risk 
factors had an effect on choosing between metformin and sulfonylureas independent of all 
measured covariates. Unmeasured risk factors for breast cancer included BMI, smoking, 
alcohol use, family history of breast cancer, parity, and age at first birth. We examined the 
impact of two major unmeasured confounders, BMI and smoking using the MCBS survey 
and found that these did not affect choice of antidiabetic treatment, suggesting little potential 
for unmeasured confounding. Unfortunately, the MCBS survey did not capture information 
on all known risk factors for breast cancer.
This study is also limited due to lack of data on breast cancer subtypes. BMI was found to be 
associated with hormone receptor–positive breast cancer among postmenopausal women, 
but not other subtypes.44,45 Thus, without breast cancer subtype data, we were unable to 
further explore the association between metformin, BMI, and subtypes of breast cancer. 
Despite the fact that not all Medicare beneficiaries enroll in part D drug plans, our results 
can be generalized to US older women or older Caucasian women residing in other 
countries. Given the small size of women of Black or other races in our study and subtype 
breast cancer varied by age and race, future research in Black, other races, and younger 
populations is warranted.
Another limitation is detection bias due to differential utilization of screening 
mammography. We examined the frequency of patients who underwent screening for breast 
cancer and found that metformin initiators were more likely to be screened for breast cancer 
before and after initiation (eTable 8). Greater utilization of screening mammography in 
metformin initiators before initiation may lead to a lower risk of breast cancer in metformin 
initiators at the time of starting follow-up because more women with asymptomatic breast 
cancer are excluded due to screening. This cannot explain our finding of no association 
between metformin and breast cancer. On the other hand, greater utilization of screening 
mammography in metformin initiators after initiation would lead to more breast cancer cases 
detected shortly after treatment initiation. As a result, metformin initiators may have an 
increased risk of breast cancer immediately following treatment initiation but a lower risk of 
breast cancer after the initial period compared with sulfonylureas initiators. We examined 
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the effect of metformin on breast cancer over time (Figure 1 and eFigure 4) and did not 
observe this pattern.
In conclusion, our findings suggest that initiation of metformin may not be associated with a 
short-term reduction in the risk for breast cancer among women aged 65 years or older when 
compared with initiation of sulfonylureas. We acknowledge that our study is limited by a 
short treatment and follow-up time, the former mainly a function of real-world treatment 
dynamics in older adults with type 2 diabetes. Randomized clinical trials have been initiated 
to evaluate metformin’s benefit on cancer incidence and will provide more definitive 
answers.
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Propensity score weighted hazard ratios (HR) and 95% confidence intervals (CIs) comparing 
metformin initiators vs sulfonylureas initiators since follow-up in the as-treated analysis, 
stratified by follow-up time (A) and by age group, race, and baseline use of statins (B). The 
results based on the intention-to-treat analysis are shown in eFigure 4.
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